NASDAQ:TORC - resTORbio Stock Price, Forecast & News

resTORbio trades on the NASDAQ under the ticker symbol "TORC."

resTORbio, Inc. (NASDAQ:TORC) issued its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.14. View resTORbio's Earnings History.

resTORbio is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for resTORbio.

4 brokers have issued 12-month price targets for resTORbio's stock. Their forecasts range from $3.00 to $28.00. On average, they expect resTORbio's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 961.6% from the stock's current price. View Analyst Price Targets for resTORbio.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for resTORbio.

Media stories about TORC stock have been trending somewhat negative this week, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. resTORbio earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for resTORbio.

resTORbio saw a decline in short interest in December. As of December 31st, there was short interest totalling 1,240,000 shares, a decline of 8.1% from the December 15th total of 1,350,000 shares. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is currently 0.7 days. Currently, 4.4% of the company's stock are sold short. View resTORbio's Current Options Chain.

Some companies that are related to resTORbio include Theratechnologies (THTX), Tyme Technologies (TYME), GlycoMimetics (GLYC), Chiasma (CHMA), XOMA (XOMA), IDEAYA Biosciences (IDYA), Athersys (ATHX), Protagonist Therapeutics (PTGX), Bicycle Therapeutics (BCYC), Five Prime Therapeutics (FPRX), Arbutus Biopharma (ABUS), Ovid Therapeutics (OVID), Nature's Sunshine Products (NATR), Arcturus Therapeutics (ARCT) and Aravive (ARAV).

Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include Novavax (NVAX), Viking Therapeutics (VKTX), vTv Therapeutics (VTVT), ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX), Cytokinetics (CYTK), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Opko Health (OPK) and Progenics Pharmaceuticals (PGNX).

(TORC) raised $86 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

resTORbio's stock is owned by many different of institutional and retail investors. Top institutional investors include Brave Asset Management Inc. (0.06%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.

TORC stock was bought by a variety of institutional investors in the last quarter, including Brave Asset Management Inc.. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio.

Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TORC stock can currently be purchased for approximately $1.46.

resTORbio has a market capitalization of $53.21 million. The company earns $-37,610,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About resTORbio.

The official website for resTORbio is http://www.restorbio.com/.

resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528.